| Assessment Status | Rapid Review Complete |
| HTA ID | 24036 |
| Drug | Dispersible tablet (DT) (dolutegravir sodium, abacavir sulphate, and lamivudine). HTA ID: 24036 |
| Brand | Triumeq® |
| Indication | Triumeq® DT is indicated for Human Immunodeficiency Virus type 1 (HIV-1) infection in children of at least three months of age and weighing at least 6 kg to less than 25 kg |
| Assessment Process | |
| Rapid review commissioned | 13/09/2024 |
| Rapid review completed | 18/10/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Triumeq® DT not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
